Success Metrics

Clinical Success Rate

75.0%

Based on 3 completed trials

Completion Rate

75%(3/4)

Active Trials

0(0%)

Results Posted

100%(3 trials)

Terminated

1(25%)

Phase Distribution

Ph phase_1

25%

Ph phase_2

75%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Phase 1Safety & dosage

1(25.0%)

Phase 2Efficacy & side effects

3(75.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(3)

Terminated(1)

Detailed Status

Completed3

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

75.0%

Most Advanced

Phase 2

Trials by Phase

Phase 11 (25.0%)

Phase 23 (75.0%)

Trials by Status

terminated125%

completed375%

Recent Activity

0 active trials

Showing 4 of 4

terminatedphase_2

Clinical Trials (4)

Showing 4 of 4 trials

NCT02378038Phase 2

PNT2258 for Treatment of Patients With Richter's Transformation (Brighton)

Terminated

NCT02226965Phase 2

PNT2258 for Treatment of Patients With r/r DLBCL (Wolverine)

Completed

NCT01733238Phase 2

Study of PNT2258 for Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma

Completed

NCT01191775Phase 1

A Study of PNT2258 in Patients With Advanced Solid Tumors

Completed

All 4 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 4